Carl Koschmann is an Oncology physician affiliated with University of Michigan. OpenAlex indexes 480 publications with 4,828 citations (h-index 39); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 E Medical Center Dr
Ann Arbor, MI 481095000
Telephone
734-936-4000Registry record last updated 7 Nov 2019.
Clinical trials
- Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma
Sponsor: University of Michigan Rogel Cancer Center
- A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
Sponsor: University of Michigan Rogel Cancer Center
- Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations
Sponsor: University of Michigan Rogel Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Blueprint Medicines CorporationProgram year20233 payments
- Blueprint Medicines CorporationProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
4 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma
University of Michigan at Ann Arbor
FY2026$473,500R01NS124607 - Targeting EGFR/FOXG1-mediated resistance to ONC201 in H3K27M-mutant diffuse midline glioma
University of Michigan at Ann Arbor
FY2025$426,151R01NS124607 - The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma
University of Michigan at Ann Arbor
FY2025$390,000R01NS119231
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
Journal of Clinical Investigation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Moshe Talpaz, MD
University of Michigan
William Herman, MD
University of Michigan
Max Wicha, MD
University of Michigan
Dinesh Khanna, MD
University of Michigan
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”